News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
296,246 Results
Type
Article (14396)
Company Profile (109)
Press Release (281741)
Section
Business (97326)
Career Advice (471)
Deals (17429)
Drug Delivery (64)
Drug Development (39876)
Employer Resources (49)
FDA (7054)
Job Trends (6550)
News (166065)
Policy (15460)
Tag
Academia (495)
Alliances (26592)
Alzheimer's disease (432)
Approvals (7064)
Artificial intelligence (76)
Bankruptcy (146)
Best Places to Work (4652)
Breast cancer (72)
Cancer (524)
Cardiovascular disease (50)
Career advice (413)
Cell therapy (72)
Clinical research (33318)
Collaboration (256)
Compensation (96)
COVID-19 (854)
C-suite (78)
Data (511)
Diabetes (71)
Diagnostics (1714)
Drug discovery (48)
Drug pricing (60)
Earnings (35201)
Events (40882)
Executive appointments (274)
FDA (7363)
Funding (176)
Gene therapy (81)
GLP-1 (325)
Government (1398)
Healthcare (4161)
Infectious disease (878)
Inflammatory bowel disease (55)
Interviews (58)
IPO (6712)
Job creations (2129)
Job search strategy (379)
Layoffs (172)
Legal (3767)
Lung cancer (75)
Manufacturing (127)
Medical device (2225)
Medtech (2228)
Mergers & acquisitions (10849)
Metabolic disorders (214)
Neuroscience (569)
NextGen: Class of 2025 (1692)
Non-profit (629)
Northern California (596)
Obesity (125)
Opinion (114)
Patents (72)
People (30524)
Pharmaceutical (67)
Phase I (8850)
Phase II (14184)
Phase III (12440)
Pipeline (258)
Policy (48)
Postmarket research (1446)
Preclinical (3534)
Radiopharmaceuticals (128)
Rare diseases (124)
Real estate (2900)
Regulatory (10957)
Research institute (600)
Resumes & cover letters (55)
Southern California (584)
Startups (1844)
United States (5812)
Vaccines (135)
Weight loss (86)
Date
Today (49)
Last 7 days (165)
Last 30 days (791)
Last 365 days (13874)
2025 (702)
2024 (14069)
2023 (16101)
2022 (22799)
2021 (23374)
2020 (21938)
2019 (16683)
2018 (13050)
2017 (15468)
2016 (14651)
2015 (17260)
2014 (13929)
2013 (11943)
2012 (12847)
2011 (13344)
2010 (12125)
Location
Africa (337)
Arizona (46)
Asia (30665)
Australia (3964)
California (1395)
Canada (796)
China (222)
Colorado (52)
Connecticut (60)
Europe (45136)
Florida (217)
Illinois (152)
Indiana (104)
Japan (78)
Kansas (57)
Maryland (239)
Massachusetts (1200)
Minnesota (90)
New Jersey (580)
New York (416)
North Carolina (340)
Northern California (596)
Pennsylvania (357)
South America (551)
Southern California (584)
Texas (178)
Virginia (49)
Washington State (87)
296,246 Results for "salix pharmaceuticals ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC).
May 17, 2024
·
4 min read
Business
Salix Pharmaceuticals Partners with Bellamy Young
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its partnership with award-winning actor Bellamy Young, who is speaking out to help educate people who are impacted by hepatic encephalopathy (HE), caused by cirrhosis.
October 4, 2023
·
5 min read
Business
Salix Announces 2024 Gastrointestinal Health Scholars Program
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the opening of the 2024 Salix Gastrointestinal Health Scholars Program application period.
February 12, 2024
·
3 min read
Business
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Bausch Health Companies Inc. today announced award-winning actor, Bellamy Young, as the brand ambassador in a new campaign to raise awareness of Xifaxan, the first and only FDA approved medication to reduce the risk of overt hepatic encephalopathy (OHE) recurrence in adults.
May 9, 2024
·
6 min read
Press Releases
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
December 11, 2024
·
3 min read
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
Salix Pharmaceuticals today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021.
October 10, 2023
·
5 min read
Press Releases
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
November 18, 2024
·
3 min read
Business
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program.
July 11, 2023
·
4 min read
Press Releases
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
December 3, 2024
·
15 min read
Press Releases
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
October 28, 2024
·
1 min read
1 of 29,625
Next
